• 5 min read
• Published on 15 April 2026
Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article
AI-Driven Pharma Stocks | Pipeline Innovation
The race to modernise medicine is fundamentally changing how we evaluate pharmaceutical shares.
The lab bottleneck. Old-school drug discovery is a slow, costly grind. Sinking billions of pounds into a decade of waiting often ends in clinical failure, leaving budgets completely wrecked.
The tech pivot. Major drugmakers are finally waking up. They're partnering with tech heavyweights to run computational models, turning blind guesswork into targeted science.
The dual play. This isn't just about buying traditional medical stocks. The smart money is targeting a blend of healthcare giants and cloud infrastructure providers, offering investors in Africa a unique entry point.
The reality check. Algorithms can't guarantee biological success. Clinical trials could still fail, and regulatory red tape might stall approvals, meaning these investments carry real financial risks.
For decades, I have watched pharmaceutical giants throw billions of pounds at a wall just to see what sticks. The traditional drug discovery process is, quite frankly, a commercial tragedy. You spend ten years and a small fortune developing a single molecule, only to watch it fail spectacularly in phase three clinical trials. It is a terrible way to run a business.
Then, the landscape shifted.
When Novo Nordisk partnered with OpenAI, it was a sudden wake-up call for the entire industry. I think it proved that the old guard finally realised human guesswork is no longer sufficient.
To me, the real story is not just the science. It is the underlying economics. By deploying generative artificial intelligence to sift through vast oceans of biological data, drugmakers might actually identify viable targets before they waste a decade in a laboratory. This computational approach could fundamentally alter the time and cost required to bring medicines to market.
Algorithms do not cure diseases, but they might just cure the pharmaceutical industry's horrific failure rates.
Naturally, smart money is already looking at who stands to benefit. If you want a pragmatic approach, you might explore the AI-Driven Pharma Stocks | Pipeline Innovation basket. It is a carefully selected group that spans two distinct but connected worlds.
First, you have the drugmakers themselves. Eli Lilly boasts an incredibly deep pipeline and is aggressively using digital platforms to sharpen its competitive edge. Pfizer is optimising clinical trials with machine learning, hoping to squeeze out marginal gains that could translate into serious long-term value. Then there is Biogen, leaning heavily on data to navigate the notoriously brutal field of neurological disease.
But the genius of this transition lies in the infrastructure. Drugmakers cannot run these immense AI models on standard office computers. They need colossal computing power. That is why technology firms like Snowflake and Arista Networks are becoming indispensable to modern healthcare. They provide the digital plumbing. If pharma's appetite for AI grows, demand for these backend services may well follow suit.
Let me be entirely clear. Biology is stubbornly complex, and adopting new technology does not eliminate investment risk.
Even a drug designed by a supercomputer can fail a human trial, and regulatory bodies can still deny approvals. Share prices could easily fall, and you might lose money. These investments should be viewed as long-term allocations, not quick speculative bets.
I firmly believe the integration of AI in healthcare is not a passing fad. It is a structural evolution. But as with all structural changes, the road ahead will be rocky. Invest with a clear head, because while the potential here is fascinating, the market takes no prisoners.
View the full Basket:AI-Driven Pharma Stocks | Pipeline Innovation
View the full Basket:AI-Driven Pharma Stocks | Pipeline Innovation
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article